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Objectives: The 2006 update of the DOQI guidelines has stated that in patients with end-stage renal disease, autogenous
radial-cephalic, or brachial-cephalic fistulas are the preferred access modalities, followed by transposed brachial-basilic
(TBB) fistulas and prosthetic arteriovenous (AV) grafts. AV grafts are in general least preferred; however, there is very
limited data comparing directly the last two modalities. The aim of the present study is to compare outcomes of the TBB
fistula and the Vectra Vascular Access Graft.
Methods: Seventy-six patients had a prosthetic brachial-axillary Vectra graft placed, while in 41 patients brachial-basilic
upper arm transposition was performed. Graft surveillance to detect a failing/failed access was followed by endovascular
treatment, rheolytic thrombectomy (AngioJet, Possis Medical), and/or angioplasty  stenting of the responsible
anatomical lesion(s).
Results: Use of Vectra grafts and TBB fistulas started after a median (interquartile range) of 14 (7-30) and 70 (52-102)
days, respectively (P< .001), as early as the operative day in some patients with grafts. Postoperative complications were
more frequent in TBB fistulas and late complications (mainly access thrombosis) in Vectra grafts. Total number of
thrombectomy sessions performed for graft or fistula occlusion was 45 and 7, respectively (P  .032); total number of
isolated angioplasty sessions, performed for failing graft or fistula was 31 and 45, respectively (P  .004). Although
primary patency of the two access modalities was equivalent, primary assisted patency was significantly reduced in Vectra
grafts (70% at 12 months and 58% at 18 months), compared with TBB fistulas (82% at 12 months and 78% at 18 months,
P  .033); however, as a result of endovascular intervention, secondary patency rates at 12 months (87% vs 88%) and 18
months (87% vs 83%) were equivalent (P .91). Presence of arterial anastomosis stenosis treated with angioplasty at any
stage had a significant negative predictive value on secondary patency rates at 12 and 18 months which were 61%,
compared with 96% for Vectra grafts that had any intra-graft, venous outflow, draining or central vein stenosis treated
with angioplasty at any stage (P  .010).
Conclusions: Aggressive graft surveillance and endovascular treatment methods can yield equivalent long-term secondary
patency rates between Vectra graft and TBB fistulas. The advantage of earlier use of Vectra graft must be balanced against
the need for more frequent secondary interventions and the risk of graft infection. (J Vasc Surg 2008;47:407-14.)There is no doubt that in patients with end-stage renal
disease (ESRD), maintenance of an adequate vascular ac-
cess is of utmost importance. The Vascular Access Work
Group of the National Kidney Foundation (NKF) has
repeatedly concluded that quality of life and overall out-
comes for hemodialysis patients could be improved signif-
icantly by achieving two primary goals: (1) increasing the
placement of autogenous arteriovenous (AV) fistulae; and
(2) detecting access dysfunction prior to access thrombo-
sis.1,2 It has been suggested that the order of access prefer-
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doi:10.1016/j.jvs.2007.09.061ence in ESRD patients or those patients expected to be-
come hemodialysis dependent is radial-cephalic fistula, fol-
lowed by brachial-cephalic fistula.2,3 If it is not possible to
establish either of these fistula types, the 2006 guidelines
update recommended the use of the transposed brachial-
basilic vein (TBB) fistula to be preferred over prosthetic AV
grafts.3 Regarding the second goal, graft surveillance using
clinical and hemodynamic parameters is currently per-
formed routinely, followed by endovascular management
of the responsible lesion. The same treatment modalities
are used in thrombosed AV grafts after thrombolysis, per-
formed almost exclusively by mechanical means.4 Addi-
tional advances include the use of AV grafts that can be
cannulated within the first day after implantation.5,6
At present, it remains unclear if TBB fistula patency
rates are better than those of prosthetic grafts,7 especially in
the era of routine access surveillance and endovascular
management. This stimulated us to perform the present
study with the aim of comparing patency rates of the TBB
fistula with a polyetherurethaneurea vascular access pros-
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Murray Hill, NJ), specially designed to provide early access
and rapid hemostasis, both access modalities being under
an aggressive surveillance and endovascular treatment pro-
tocol.
METHODS
Seventy-six consecutive patients (39 females and 37
males) that had a prosthetic brachial-axillary Vectra Vascu-
lar Access Graft (C. R. Bard, Inc, Murray Hill, NJ) placed
and 41 patients (18 females and 23 males) that had
brachial-basilic vein fistula transposition, performed during
2004 and 2005 inclusive, were included in this controlled-
comparative study. In an effort to minimize introduction of
confounding variables, only prosthetic brachial-axillary
Vectra grafts were included, since their inflow and outflow
matched those of the TBB fistulas; redo Vectra grafts were
excluded. Table I shows the patient characteristics of the
two study groups. Twenty nine (38%) and nine (22%)
patients of the Vectra and TBB groups, respectively, had no
history of a previous prosthetic graft or autogenous fistula
and were not candidates for creation of a primary autoge-
nous fistula, based on preoperative imaging of their arm
veins with venogram or ultrasound (vein diameter less than
2.5 mm). The remainder had one or more access surgeries
performed and were not candidates for creation of a pri-
mary autogenous fistula, based on the same criteria. Left
arm was selected in the majority of cases (n 79, 68%), the
right one (n  38) being a second choice when the left
(non-dominant side for the majority of patients) arm had
been previously used. All grafts implanted were 5 or 6 mm
in diameter.
Vectra Vascular Access Graft is a trilayered graft, com-
posed of Thoralon, a proprietary blend of segmented poly-
etherurethaneurea and a siloxane containing a surface-
modifying additive (SMA). Vectra has self-sealing
properties allowing early cannulation. The microporous
outer layer is designed to enhance graft anchoring and kink
resistance, the solid middle layer is responsible for the
self-sealing graft properties, while the microporous blood-
contacting inner layer contains an SMA-rich environment
designed to minimize platelet adhesion. Manufacturer im-
plantation guidelines were followed to optimize graft place-
ment, including prevention of kinking. All anastomoses
were performed with 6-0 polypropylene suture (Prolene,
Ethicon Inc, Somerville, NJ). In 69 grafts (91%), the
Table I. Difference in patient characteristics of the transpo
Access type
Age
(mean  SD y)
Gender
(male/female)
TBB fistula (n  41) 59.4  16.5 18/23
Vectra graft (n  76) 61.6  16.0 39/37
P .48 .44procedure was performed under interscalene brachialplexus regional  local anesthesia with intravenous seda-
tion. In seven (9%) cases, anesthesia was general.
Brachial-basilic vein fistula transposition was performed
in all but one patient as a one stage procedure, involving a
transverse antecubital fossa incision that was extended up
on themedial aspect of the arm (“hockey-stick” incision) so
that the basilic vein was mobilized in its entire length by
dividing all tributaries. The basilic vein was subsequently
disconnected and transposed into a lateral subcutaneous
tunnel and anastomosed to the brachial artery in an end-
to-side fashion with 7-0 polypropylene suture (Prolene,
Ethicon Inc, Somerville, NJ).8,9 In 34 patients (83%), the
procedure was performed under interscalene brachial
plexus regional  local anesthesia with intravenous seda-
tion, while in the remainder seven patients (17%) anesthesia
was general.
Access surveillance was performed by using clinical and
hemodialysis parameters to detect a failing/failed access.
Identification of high dynamic venous pressures (300
mmHg) or suboptimal blood flow (400 ml/min) during
hemodialysis were the most frequent indications for inter-
vention, followed by prolonged bleeding time after hemo-
dialysis and abnormal findings on clinical examination, such
as weak or absent thrill, ipsilateral arm edema suggestive of
a central venous stenosis and access pain during hemodial-
ysis. Recirculation was rarely encountered.1 Frequently,
more than one criterion was present.
Endovascular treatment was subsequently performed
under local anesthesia with sedation as an outpatient pro-
cedure. Rheolytic thrombectomy for access occlusion was
performed with the AngioJet AVX catheter (Possis Medical
Inc, Minneapolis, Minn) activated by the AngioJet throm-
bectomy system (3000 series, Possis Medical Inc, Minne-
apolis, Minn), followed by angioplasty ( stenting) of the
anatomical lesion (arterial anastomosis, graft or fistula
body, venous outflow, draining or central veins) responsi-
ble for the thrombotic event.3 Isolated angioplasty (
stenting) of the anatomical lesion (graft or fistula body,
venous outflow, draining or central veins) was performed
for failing accesses, with an arterial anastomotic angioplasty
performed occasionally. For practical purposes, the conflu-
ence of the basilic vein with brachial vein was considered as
venous outflow.
Our technique, published previously in the Journal,10
is a modification of Beathard’s technique,11 and compro-
brachio-basilic vein (TBB) fistula and Vectra graft groups
History of
revious graft or
fistula (%)
Access side
(L/R)
Regional
anesthesia (%)
32 (78%) 32/9 34 (83)
47 (62%) 47/29 69 (91)
.074 .074 .24sed
pmised, briefly, by the following steps:
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the venous anastomosis. (2) Arterial access and embolec-
tomy: a hydrophilic wire is passed under fluoroscopy to the
radial artery, followed by arterial embolectomy. (3) Me-
chanical thrombolysis of the venous side. (4) Angioplasty of
the stenotic lesion (arterial anastomosis, graft or fistula,
venous outflow, draining or central veins) (Fig 1). (5)
Completion angiogram. (6) Hemostasis.
After successful thrombolysis, graft or fistulas can be
immediately used for hemodialysis.
All patients were followed up to the end of secondary
patency (final thrombotic event or access abandonment),
graft removal (because of infection) or death. The study
was approved by the hospital institutional review board.
Statistics. All data were entered into a Microsoft Of-
fice Excel database (Microsoft Inc, Redmond, Wash) and
analyzed with SPSS 14.0 for Windows (SPSS Inc, Chicago,
Ill). Reporting Standards for Arterio-Venous Accesses of
the Society for Vascular Surgery and the American Associ-
ation for Vascular Surgery were used to define graft
patency.12
Primary patency was defined as fully functional access,
the first episode of failure or thrombosis being used to
determine this. Primary assisted patency was defined as
patent access without thrombectomy, including those in
which any intervention had been performed to prevent
what was perceived to be impending failure. Secondary
patency was defined as accesses that were patent after
thrombectomy, the terminal thrombotic event being taken
into account to estimate secondary access patency rates.
Functional secondary access patency was defined as above
but also took into account non-functional but patent ac-
cesses and grafts removed for late infection. Access patency
rates were calculated with the Kaplan-Meier method and
compared with the log-rank (Mantel-Cox) test. Multivari-
ate analysis of the effect of clinical parameters on patency
rates was performed with the Cox regression method (for-
ward and backward Wald models). Categorical data were
Fig 1. This figure shows the Kaplan-Meier curves of primary
patency rates of TBB fistulas and Vectra grafts. Primary patency of
TBB fistulas and the Vectra graft was equal (P .62). Error bars of
the survival curves represent standard error, while the number of
patients at risk at each interval is also shown.analyzed with the 2 or Fisher exact test, where appropriate;numerical data were analyzed the t test or Mann-Whitney
test, where appropriate. A P value less than .05 was consid-
ered as statistically significant. Two-tailed statistical tests
were always used.
RESULTS
Complications. Early complications were more fre-
quent in TBB fistulas than Vectra graft, while a reverse
trend was observed for late complications (Table II). Steal
syndrome and venous hypertension were both more prev-
alent in TBB fistulas and access thrombosis was more
prevalent in Vectra grafts. One fistula (2.4%) had slow
maturation but was rescued, with percutaneous angioplasty
of the arterial anastomosis.
Access use. Use of Vectra grafts and TBB fistulas
started after amedian (interquartile range) of 14 (7-30) and
70 (52-102) days, respectively (P  .001), as soon as from
the day of surgery in four patients with Vectra grafts and
day one in four additional patients. No TBB fistula matured
to allow dialysis for the first 3 postoperative weeks. Central
catheters were usually removed after three successful ses-
sions of hemodialysis.
Endovascular procedures. Table III shows the distri-
bution of angioplasty and stenting procedures in failing
TBB fistulas and Vectra grafts that underwent isolated
angioplasty. Distribution of such procedures performed in
thrombosed (failed) TBB fistulas and Vectra grafts that
underwent thrombectomy and ancillary endovascular pro-
cedures is also shown. Total number of thrombectomy
sessions performed for graft or fistula occlusion was 45 and
7, respectively (P  .032, Mann-Whitney test); total num-
ber of isolated angioplasty sessions, (not associated with
thrombosis), performed for failing graft or fistula was 31
and 45, respectively (P  .004, Mann-Whitney test). One
TBB fistula arterial anastomosis stenosis, resistant to percu-
taneous angioplasty, was successfully revised surgically.
Procedures were tolerated well, with only two complica-
tions (2/130, 1.5%), a fistula body stenosis rupture that
was managed with placement of a stent graft and a distal
embolization that occurred during mechanical thromboly-
sis of a Vectra graft that was managed successfully with
mechanical thrombolysis using the AngioJet device.
Pattern of stenotic lesions. Venous outflow stenosis
was the most common anatomical lesion associated with
graft failure or thrombosis; fistula body and draining vein
stenosis to a lesser extent were mainly responsible for fistula
failure or thrombosis. Venous outflow stenoses were signif-
icantly more often in thrombosed and failing Vectra grafts
(93% and 97%, respectively), compared to thrombosed and
failing fistulas (43% and 45%, respectively). Draining vein
stenosis followed a similar pattern. In contrast, central vein
stenosis was treated more often in fistulas compared with
Vectra grafts, but the difference reached only marginal
statistical significance in failing grafts or fistulas. Central
vein angioplasty was performed more often in secondary or
tertiary failing accesses (9/26, 35%) compared with pri-
mary failing accesses (0/10, 0%, P  .039, Fisher exact
test). Arterial anastomosis angioplasty was performed more
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Vectra grafts (3.2%), P  .001. Fistulas followed a similar
pattern, although the difference did not reach statistical
significance. Total number of complications, events and
interventions per patient-year was similar in TBB fistulas
and Vectra grafts, 1.35 and 1.32, respectively.
Patency results. Patency results are shown in Table
Table II. Distribution of early and late postoperative and
basilic vein (TBB) fistulas and Vectra grafts
Complication
Number (%)
TBB fistulas (n 41) V
Bleeding* 4 (9.8%)†
Steal syndrome 3 (7.3%)‡
Venous
hypertension
6 (15%)
Aneurysm or
pseudoaneurysm
4 (9.8%)§
Access thrombosis 7 (17%)
Late infection 0 (0%)
Other 3 (7.3%)
All accesses¶ 19 (46%)
*All, but one, were late and hemodialysis-related.
†One wound exploration.
‡All were mild.
§One fistula was ligated.
□One anastomotic pseudoaneurysm.
¶Some accesses developed more than on complication.
Table III. Distribution of angioplasty and stenting proced
Group
Angiopl
Arterial
anastomosis Graft
Failing TBB fistulas
(n  19, 47 sessions)
6 (13) 25 (53)
Thrombosed TBB fistulas
(n  5, 7 sessions)
3 (43) 4 (57)
P .081 1.00
Odds ratio (95% CI) 5.1
(0.91-28.8)
1.17
(0.24-5.83)
Failing grafts (n  17, 31
sessions)
1 (3.2) 13 (42)
Thrombosed grafts
(n  22, 45 sessions)
16 (36) 22 (49)
P .001 .55
Odds ratio (95% CI) 16.6
(2.1-133.0)
1.32
(0.53-3.33)
P (failing TBB fistulas vs
failing grafts)
.23 .33
P (thrombosed TBB
fistulas vs thrombosed
grafts)
.70 1.00
Distribution of angioplasty and stenting procedures (1) failing transpose
angioplasty and (2) thrombosed (failed) TBB fistulas and Vectra grafts tha
values appear in bold.
*Venous outflow and subclavian stenosis.
†Venous outflow stenosis. One additional stent-graft was placed for post-an
‡Venous outflow stenosis. Two additional stent-grafts were placed for graft
§Venous outflow (n  8), arterial (n  2), and graft (n  1) stenosis.IV. Primary patency of TBB fistulas and the Vectra graft wasequal (Fig 1, P .62). Primary assisted patency was signif-
icantly reduced in Vectra grafts, compared to TBB fistulas
(Fig 2), P  .033, however, as a result of the multiple
interventions described above, secondary patency rate at 12
and 18 months was equivalent. This patency rate equiva-
lency persisted despite the necessity to remove the Vectra
graft for late infection in five patients (6.6%) (P  .31,
odialysis-related complications in transposed brachio-
P Odds ratio (95% CI)grafts (n 76)
(2.6%) 0.18 4 (0.70-22.85)
(0%) 0.04 N/A
(1.3%) 0.007 12.86 (1.49-110.90)
(2.6%)□ 0.18 4 (0.70-22.85)
(34%) 0.049 2.53 (0.99-6.48)
(6.6%) 0.16 N/A
(1.3) 0.12 5.92 (0.60-58.86)
(42%) 0.66 0.84 (0.39-1.81)
rocedures (n[%]]
Stenting
(n [%])
enous
tflow
Draining
veins Central veins
(45) 7 (15) 15 (32) 2 (4.3)*
(43) 1 (14) 2 (29) 1 (14)†
.00 1.00 1.00 .346
19-4.62)
0.95
(0.10-9.17)
0.85
(0.15-4.91)
3.8
(0.29-47.89)
(97) 13 (42) 4 (13) 1 (3.2)‡
(93) 22 (49) 9 (20.0) 6 (13)§
.64 .64 .54 .23
05-4.71)
1.32
(0.53-3.33)
1.69
(0.47-6.06)
4.6
(0.53-40.42)
.001 .007 .056 1.00
.004 .12 .63 1.00
hio-basilic vein (TBB) fistulas and Vectra grafts that underwent isolated
rwent thrombectomy and ancillary endovascular procedures. Significant P
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Volume 47, Number 2 Kakkos et al 411Presence of arterial anastomosis stenosis treated with
angioplasty at any stage had a significant negative predictive
value on secondary patency rates of Vectra grafts at 12 and
Table IV. Results of primary and primary assisted patency
18 months (Kaplan-Meier method) in patients with transp
Patency Access group
Primary TBB fistula
Vectra graft
Primary assisted TBB fistula
Vectra graft
Secondary TBB fistula
Vectra graft
Secondary functional TBB fistula
Vectra graft
Fig 2. This figure shows the Kaplan-Meier curves of primary
assisted patency rates of TBB fistulas and Vectra grafts. Primary
assisted patency was significantly reduced in Vectra grafts, com-
pared with TBB fistulas P .033. Error bars of the survival curves
represent standard error, while the number of patients at risk at
each interval is also shown.
Fig 3. This figure shows the Kaplan-Meier curves of functional
secondary patency rates of TBB fistulas and Vectra grafts; equiva-
lent rates at 12 and 18 months were observed. Error bars of the
survival curves represent standard error, while the number of
patients at risk at each interval is also shown.18 months, which were 61% compared with 96% for Vectragrafts that had any intra-graft, venous outflow, draining, or
central vein stenosis treated with angioplasty at any stage (P
 .010) and 92% for Vectra grafts that had no interventions
performed (P  .014, Fig 4). Presence of individual graft,
venous outflow, draining, or central vein stenoses treated
with angioplasty did not have any effect on secondary
patency rates of Vectra grafts (P  .05). In TBB fistulas,
only angioplasty for draining vein stenosis had a negative
effect on secondary patency rate that reached marginal
statistical significance (P  .049); secondary patency rate
for TBB fistulas that had angioplasty for draining vein
stenosis was 38% at 18 months, compared with 91% for
TBB fistulas that did not necessitate angioplasty for drain-
ing vein stenosis. Presence of individual arterial anastomo-
sis, fistula body, venous outflow, and central vein stenoses
treated with angioplasty did not have any negative effect on
secondary patency rates for TBB fistulas (P  .05).
In TBB fistulas, age had a significant impact on primary
assisted patency (but not secondary patency), 59% at 18
months in patients older than 59 years and 94% at 18
months in patients that were 59 years old or younger (P 
ondary, and functional secondary patency at 1, 12, and
brachio-basilic vein (TBB) fistula and Vectra grafts
Time
P12 mo 18 mo
46% 31% .62
50% 26%
82% 78% .033
70% 58%
88% 84% .91
87% 87%
88% 84% .31
81% 78%
Fig 4. This figure demonstrates the negative predictive value of
arterial anastomotic stenosis detected and treated with angioplasty
at any stage during Vectra graft’s life on secondary patency rates;
these were 60.6% at 12 and 18 months compared with 92.4% for
grafts that had no interventions performed (P  .014) and 95.5%
for patients that had any intra-graft, venous outflow, draining or
central vein stenoses treated with angioplasty at any stage (P 
.010). Error bars of the survival curves represent standard error,
while the number of patients at risk at each interval is also shown., sec
osed
1 mo
100%
92%
100%
93%
100%
97%
100%.03). Gender, history of previous vascular access procedures
JOURNAL OF VASCULAR SURGERY
February 2008412 Kakkos et alor infection, fistula site, side or short- and long-term fistula
complications had no effect on primary assisted or second-
ary patency rates (P  .05) of TBB fistulas. Gender, age,
history of previous vascular access procedures or infection,
graft site, side or short- and long-term graft complications
had no effect on primary assisted or secondary patency rates
(P  .05) of Vectra grafts.
Multivariate analysis, which included access type (Vec-
tra graft or TBB fistula), gender, age, history of previous
vascular access procedures or infection, access site, side or
short- and long-term access complications as independent
variables, identified access type (TBB fistula) as the single
predictor of primary assisted patency (Beta.878, SE
.430, Wald  4.17, P  .041, exp (B) (relative risk) 
0.416, 95% CI 0.179-0.965). Multivariate analysis, which
included the same variables tested for primary assisted
patency and also the particular type of angioplasty per-
formed to increase primary and primary assisted patency,
identified arterial anastomosis angioplasty as the single
predictor of secondary patency (Beta  1.421, SE 
.541, Wald  6.89, P  .009, exp(B) (relative risk) 
0.242, 95% CI 0.084-0.698).
DISCUSSION
The present study showed that aggressive access sur-
veillance and endovascular treatment increases significantly
secondary patency rates of Vectra vascular access grafts and
TBB fistulas, with medium-term results at 12 and 18
months being equivalent.
Postoperative complications for prosthetic grafts were
rare. No seroma formation was seen in this series, a com-
plication seen in PTFE grafts.13,14 This is probably the
effect of the self-sealing graft properties of the solid middle
graft layer and research towards grafts with minimal
porosity is ongoing.13 On the other hand, TBB fistula
creation was associated with some morbidity, consistent
with previous studies that reported complications as high as
44% to 55% of the procedures.15,16 Steal syndrome neces-
sitating fistula ligation has been reported in 6.5% of proce-
dures.17 Long-term complications, thrombosis, and infec-
tion, however, remain the Achilles heel of prosthetic grafts.
Our prosthetic graft infection rate, 6.6% compares favor-
ably with a 16% infection rate, previously reported.18
Vectra grafts can be used as soon as the first postoper-
ative day. In this study, early graft cannulation was possible
for most grafts, with a least half of the patients being
dialyzed within 2 weeks after surgery. A variable time to
hemodialysis has been reported;5,6,19-21 in two of the pub-
lished studies cannulation time was 19 and 20 days respec-
tively.5,21 In contrast, most TBB fistulas did not mature for
almost 10 weeks, ie, five more times than the time it was
necessary for the Vectra grafts. Similar maturation times
have been previously reported,22,23 with some surgeons
allowing the fistula to mature for at least six weeks.15
Appreciation of this differential maturation time is essential
when planning an access.
Although there is substantial controversy on the opti-
mal methodology, access surveillance is recommended bymost experts and the DOQI guidelines for the early detec-
tion of failing native fistulas and prosthetic grafts to increase
primary patency rates.1-3,24-26 The same guidelines ac-
knowledge the fact that appropriate intervention with pre-
emptive percutaneous transluminal angioplasty or surgical
revision to correct stenoses dramatically reduces the rate of
AV graft thrombosis and loss,2 concept that is also sup-
ported by clinical trial results.27-29 A variety of methods,
including Duplex ultrasound, and clinical and hemody-
namic criteria, has been suggested for access surveillance.
We used multiple clinical and hemodynamic criteria, prac-
tice supported also by theDOQI guidelines;3 high dynamic
venous pressure, low flows and prolonged bleeding, in
descending frequency order, were the most common indi-
cations for performing a diagnostic access angiogram. We
had a low threshold of performing this test in order to
increase sensitivity and achieve high primary assisted and
secondary patency rates.
Being minimally invasive, thrombectomy methods are
highly effective and can be repeated several times before
surgical revision becomes mandatory.30 This is facilitated
by their excellent safety profile,11 confirmed by our study.
As expected, grafts thrombosed more frequently than fis-
tulas but required performance of isolated maintenance
angioplasty less frequently. The vast majority of accesses
had outflow stenosis, and this is consistent with previous
studies;11 unlike failing prosthetic grafts, those that were
thrombosed had a high incidence of arterial anastomosis
stenoses additionally to the presence of outflow stenosis;
autogenous fistulas followed a similar pattern. Arterial in-
flow stenoses have been recently recognized as being more
frequent than previously thought;31 The hemodynamic
severity of combined lesions is obviously worse and this
could explain our findings. Thrombosed or failing TBB
fistulas on the other hand demonstrated a high incidence of
fistula body or central vein stenoses, consistent with previ-
ous findings.7 While fistula body stenoses might have been
the result of cannulation, the higher incidence of central
vein stenoses is probably the result of higher prevalence of
previous central catheter use, since TBB fistulas are essen-
tially a tertiary access option.
Patency rates of the Vectra graft reported by the current
study compared favorably with most previous stud-
ies.5,6,19-21,32 We attribute this finding to our aggressive
surveillance policy and good results of endovascular main-
tenance, with both being the reason we achieved very good
secondary patency rates. Arterial anastomosis stenosis was
an adverse patency predictor for Vectra grafts in our study.
Further research for alternative treatment modalities and
perhaps closer monitoring of accesses with arterial inflow
stenoses might be warranted to improve their significantly
lower secondary patency rates. There are few studies that
compare directly prosthetic AV grafts with TBB fistulas.
TBB fistula has significantly better but variable primary and
secondary patency than PTFE grafts.7,16,33,34 Functional
secondary patency as low as 47% at 1 year has been re-
ported.7 In a recent review of 28 studies, Dix reported an
average 1-year primary and secondary patency rates of 72%
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been the result of patient selection or poor fistula surveil-
lance or endovascular treatment. To the best of our knowl-
edge, the only study that compared directly Vectra grafts
and TBB fistulas was performed by Wilmink in the United
Kingdom and found equivalent patency rates (50% to 60%
at 12 and 18 months).32 Our results (88% functional sec-
ondary patency at 12 months) compare favorably and
should be attributed to the aggressive access surveillance
and management.
Because our study was not randomized, recommend-
ing TBB fistula creation over a Vectra graft, in patients
that are not candidates for radiocephalic or brachioce-
phalic autogenous fistula, remains a matter of discussion.
The advantage of earlier use of a Vectra graft must be
balanced against the need for more frequent secondary
interventions and the risk of graft infection. Pending
results from randomized trials, candidates with suitable
basilic vein, should have TBB fistula performed first. In
patients with a non-suitable basilic vein a brachio-axillary
prosthetic AV graft or alternatively a loop forearm pros-
thetic AV graft (to mature the venous system) could be
used. Such a sequence, that we are currently practicing,
has better adherence with the most recent update of the
DOQI guidelines.3
In conclusion, aggressive access surveillance and endo-
vascular treatment methods can yield equivalent long-term
patency rates between Vectra grafts and TBB fistulas; how-
ever, the advantage of earlier use of Vectra graft must be
balanced against the need for more frequent secondary
interventions and the risk of graft infection. Longer
follow-up and data from randomized controlled trials will
help to refine the DOQI guidelines.
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